Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HDL Clear all
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Supplements, Placebo, or Rosuvastatin Study

NCT04846231
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Egg Effects on the Immunomodulatory Properties of HDL

NCT03577223
View directory record Official record
Conditions
Lipid Metabolism, Inflammation
Interventions
Whole Eggs, Egg White-Based Egg Substitute
Other
Lead sponsor
Fairfield University
Other
Eligibility
18 Years to 35 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fairfield, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Prolonged Fasting on Microbiome and HDL

NCT03487679
View directory record Official record
Conditions
Fasting
Interventions
Fasting
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Jun 9, 2026, 11:44 PM EDT
Completed No phase listed Observational

Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes

NCT00287404
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of North Carolina
Other
Eligibility
20 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jun 9, 2026, 11:44 PM EDT
Not listed Not applicable Interventional

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia, HoFH
Interventions
HDL Therapeutics PDS-2 System
Device
Lead sponsor
HDL Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Goji vs. Fiber on Macular Degeneration

NCT06237127
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Goji berry, Fiber
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00749788
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

NCT04271735
View directory record Official record
Conditions
Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
Interventions
Niagen, Placebo
Dietary Supplement · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

NCT00590629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Niaspan
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Corn and Heart Health Study

NCT03967990
View directory record Official record
Conditions
Gut Microbiome, Cholesterol, LDL, Cholesterol, HDL
Interventions
Refined cornmeal flour, 50/50 refined cornmeal-bran mix, Whole grain cornmeal flour
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 1 Interventional

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01554800
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
ACP-501
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 9, 2026, 11:44 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Quercetin on Metabolic Health

NCT05297032
View directory record Official record
Conditions
Quercetin, Lipid Metabolism, Aging
Interventions
Quercetin Phytosome
Dietary Supplement
Lead sponsor
Thorne HealthTech, Inc
Industry
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

NCT00986986
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions
extended release niacin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lipid Screening Study

NCT07579325
View directory record Official record
Conditions
Lipoprotein (a)
Interventions
Venipuncture
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

NCT02542176
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Freeze-dried Whole Grape Powder, Grape Powder Placebo
Other
Lead sponsor
University of Connecticut
Other
Eligibility
30 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

NCT00327002
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
LY518674
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
View directory record Official record
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jun 9, 2026, 11:44 PM EDT